A prospective double-blind randomized controlled study to examine the effects of Korean red ginseng on biological aging indicators and antioxidants in Korean postmenopausal women.

The effects of Korean red ginseng on biological aging and oxidative stress in postmenopausal women: A Double-blind Randomized Controlled Study

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

CRIS

Registry ID

KCT0006506

Enrollment

Registered

2021-08-26

Start date

2019-10-04

Completion date

Unknown

Last updated

2021-08-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Dietary Supplement : Korean red ginseng (KRG)group: KRG tablet 500mg/T, 2g/day for 8 weeks. (including ginsenoside Rb1 (8.03 mg/g), Rc (3.29 mg/g), Rb2 (2.80 mg/g), Rg3 (2.50 mg/g), Rf (1.47 mg/g),

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: 1. A person who voluntarily agrees to participate in this trial after explaining the characteristics of this clinical trial and signs the IRB-approved consent form 2. Postmenopausal women aged between 46 and 69 at the time of obtaining consent 3. Patients approved by the attending physician to participate in the study 4. Those who can complete the study without participating in other interventional studies (drugs, diet, exercise) during the study period 5. Patients without restrictions on participation in physical activity during the study period 6. Patients who can understand and use Korean naturally

Exclusion criteria

Exclusion criteria: 1. Premenopausal women under the age of 46 or over 69 2. Current Smoker 3. Alcohol (2 times a week / 3 or more drinks a day) 4. Poorly controlled hypertension (SBP>180, DBP>100) 5. Poorly controlled diabetes (fasting blood sugar >200) 6. Diagnosed with liver disease, AST, ALT more than 3 times the upper limit, or kidney disease (serum creatinine >2.0 mg/dL) 7. Those who have been diagnosed with cancer or are undergoing treatment 8. Those who have been diagnosed with cardiovascular disease or are taking medications 9. Those taking other health supplements 10. Patients with visual, hearing and speech impairments that may affect the examination 11. Others who are considered to be unable to participate in this study when judged by the person in charge of clinical research 13. Those taking hormonal drugs

Design outcomes

Primary

Measure	Time frame
DNA telomere length, mitochondria DNA copy number, total antioxidant status, total oxidative status	—

Secondary

Measure	Time frame
clinical symptoms questionnaire and complete blood count, lipid profile, liver enzyme(aspartate aminotransferase, alanine aminotransferase, gamma-glutamyltransferase ), blood uria nitrate, creatinine, glucose, urine analysis, body composition	—

Countries

Korea, Republic of

Contacts

Public ContactTaeHa Chung

Yonsei University, Wonju Severance Christian Hospital

medeus115@yonsei.ac.kr+82-33-741-0554

Outcome results